Almirall To Position Oral DMF For Psoriasis Ahead Of EU Biologics Use

Spain-based Almirall SA will roll out its as-yet unpatented fumaric acid derivative throughout Europe in the third quarter of 2017 as a first-line induction and long-term treatment for adults with moderate-to-severe chronic plaque psoriasis, offering, it says, a much cheaper option than new, highly-priced biologic therapies.

The Barcelona-based drug maker is readying plans for EU commercialization of its oral dimethyl fumarate (DMF) treatment after winning backing from the European Medicines Agency's (EMA) top advisory drug panel, the Committee for Medicinal Products for Human Use (CHMP)